CVRx Inc (CVRX) Stock Analysis

AI analysis of CVRx Inc (CVRX)

Sell

CVRx Inc is not a good buy right now due to significant financial and operational challenges. The current price is $0.8672, which is down 87.79% year-to-date. The company has a very low RSI of 19.218, indicating it is oversold, but this is coupled with a concerning forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the latest analyst ratings have downgraded the price targets significantly, with Craig-Hallum lowering it to $1.25 from $4, reflecting ongoing headwinds in sales execution and reimbursement challenges. The main risk is the high debt-to-equity ratio of 293.54%, indicating potential financial instability.

Valuation Metrics

The current forward P/E ratio for CVRx Inc (CVRX) is 0.00, compared to its 5-year average forward P/E of -5.62.

Forward P/E

Strongly Overvalued

5Y Average P/E

-5.62

Current P/E

0.00

Overvalued

-3.36

Undervalued

-7.88

Forward EV/EBITDA

Overvalued

5Y Average EV/EBITDA

-3.88

Current EV/EBITDA

-0.63

Overvalued

-1.19

Undervalued

-6.56

Forward P/S

Undervalued

5Y Average P/S

5.40

Current P/S

0.59

Overvalued

8.50

Undervalued

2.30

Alphio AI Price Scenarios for CVRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CVRX

$11.10

Scenario price

B

Base

Base · 50%CVRX

$9.61

Scenario price

B

Bear

Bear · 25%CVRX

$8.24

Scenario price

Whales holding CVRX

N

New Enterprise Associates, Inc.

+ HoldingCVRX

+0.00%

3M Return

CVRX FAQ — answered by Alphio AI

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

CVRx Inc is not a good buy right now due to significant financial and operational challenges. The current price is $0.8672, which is down 87.79% year-to-date. The company has a very low RSI of 19.218, indicating it is oversold, but this is coupled with a concerning forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the latest analyst ratings have downgraded the price targets significantly, with Craig-Hallum lowering it to $1.25 from $4, reflecting ongoing headwinds in sales execution and reimbursement challenges. The main risk is the high debt-to-equity ratio of 293.54%, indicating potential financial instability.